4
3. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Current
Opinion in Chemical Biology 2010, 14, 347-361.
was collected by vacuum filtration, washed with
additional acetonitrile, and allowed to dry. Yields of
precipitated product were recorded. The solubility of
the products in acetonitrile was not monitored, and
therefore, variability in reaction yields may be due to
solubility differences between compounds rather than
4. (a) He, L.; Li, H.; Chem, J.; Wu, X-F RSC Adv. 2014, 4,
12065-12077. (b) Maiden, T. M. M.; Harrity, J. P. A.
Org. Biomol. Chem. 2016, 14, 8014-8025.
(c)
Rohokale, R. S.; Kshirsagar, U. A. Synthesis 2016, 48,
1253-1268.
reaction performance.
6-Phenoxy-2-(piperidin-1-
yl)quinazolin-4(3H)-one (4). 1H NMR (400 MHz,
DMSO-d6): ppm 11.26 (bs, 1H), 7.45-7.37 (m, 2H),
7.37-7.32 (m, 2H), 7.33-7.29 (m, 1H), 7.20-7.14 (m,
1H), 7.07-7.01 (m, 2H), 3.67-3.52 (m, 4H), 1.65-1.47
(m, 6H). 13C NMR (150 MHz, DMSO-d6): ppm
156.8, 151.7, 130.1, 126.3, 123.5, 118.6, 117.4, 113.2,
45.8, 25.0, 23.9. MS calc’d. for C19H19N3O2, 321.15;
found, m/z 322.0 [M+H]+.
5. (a) Pendergast, W.; Johnson, J. V.; Dickerson, S. H.;
Dev, I. K.; Duch, D. S.; Ferone, R.; Hall, W. R.;
Humphrey, J.; Kelly, J. M.; Wilson, D. C. J. Med.
Chem. 1993, 36, 2279-291. (b) Somers, F.; Ouedraogo,
R.; Antoine, M.-H.; de Tullio, P.; Becker, B.; Fontaine,
J.; Damas, J.; Dupont, L.; Rigo, B.; Delarge, J.; Lebrun,
P.; Pirotte, B. J. Med. Chem. 2001, 44, 2575-2585. (c)
Alagarsamy, V.; Dhanabal, K.;
Parthaban, P.;
Anjana,G.; Deepa, G.; Murugesan, B.; Rajkumar, S.;
Beevi, A. J. J. Pharm. Pharmacol. 2007, 59, 669-677.
(d) Hess, H.-J.; Cronin, T. H.; Scriabine, A. J. Med.
Chem. 1968, 11, 130-136. (e) Hussain, M. A.; Chiu, A.
T.; Price, W. A.; Timmermans, P. B.; Shefter, E.
Pharm. Res. 1988, 5, 242-244. (f) Hörtner, S. R.;
Ritschel, T.; Stengl, B.; Kramer, C.; Schweizer, W. B.;
Wagner, B.; Kansy, M.; Klebe, G.; Diederich, F.
Angew. Chem. Int. Ed. 2007, 46, 8266-8269. (f) Liu, H.;
Gao, J.; Kool, E. T. J. Org. Chem. 2005, 70, 639-647.
6. Niculescu-Duvaz, I. Curr. Opin. Invest. Drugs 2001, 2,
693-705.
7. Ma, B.; Wang, Y.; Peng, J.; Zhu, Q. J. Org. Chem.
2011, 76, 6362-6366.
8. (a) Dean, W. D.; Papadopoulos, E. P. J. Heterocyclic
Chem. 1982, 19, 171-176. (b) Samaraj, L. I.; Bondar,
V. A.; Derkatsch, G. I. Angew. Chem. Int. Ed. Engl.
1967, 6, 86. (c) Samaraj, L. I.; Bondar, V. A.;
Derkatsch, G. I. Zh. Org. Khim. 1969, 5, 119-123. (d)
Goerdeler, J.; Richter, R. Synthesis 1978, 760-762. (e)
Croce, P. D.; Ferraccioli, R.; La Rosa, C. Heterocycles
1997, 45, 1309-1318. (f) Zeghida, W.; Debray, J.;
Chierici, S.; Dumy, P.; Demeunynck,M. J. Org. Chem.
2008, 73, 2473-2475.
9. See supplementary material
10. (a) Suhs, T.; Koenig, B. Mini-Reviews in Organic
Synthesis 2006, 3, 315-331. (b) Rasmussen, C. R.;
Villani, Jr., F. J.; Reynolds, B. E.; Plampin, J. N.; Hood,
A. R.; Hecker, L. R.; Nortey, S. O.; Hanslin, A.;
Costanzo, M. J.; Howse, Jr., R. M.; Molinari, A. J.
Synthesis 1988, 460-466. (c) Maryanoff, C. A.;
Stanzione, R. C.; Plampin, J. N.; Mills, J. E. J. Org.
Chem. 1986, 51, 1882-1884. (d) X. Deng, H.
McAllister, N. Mani, J. Org. Chem. 2009, 74, 5742-
5745.
11. Typical experimental procedure for CDI-mediated
cyclizations: The aryl or heteroaryl guanidine (1
equiv) was combined with CDI (1.05-1.1 equiv) in a
round bottom reaction flask. Acetonitrile (~0.1-0.2 M)
was added, and the open reaction was stirred in an oil
bath at the desired temperature (usually 80 °C).
Crystalline product began precipitating within minutes.
The reaction was monitored by HPLC. If starting
guanidine remained after ~2 h, 0.1 equiv aliquots of
CDI were added with continued monitoring until the
starting material was consumed. The reaction was
allowed to cool to room temperature, and the product